Advertisement
Advertisement

ZYME

ZYME logo

Zymeworks Inc.

25.59
USD
-0.29
-1.12%
Dec 17, 15:59 UTC -5
Closed
exchange

Pre-Market

25.79

+0.20
+0.79%

Zymeworks Inc. Profile

About

Zymeworks Inc. is a clinical-stage biopharmaceutical company. It engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The companys lead product candidate includes ZW25 and ZW33 which are in clinical trial stage. Zymeworks Inc. is headquartered in Vancouver, Canada.

Info & Links

CEO

Kenneth Galbraith

Headquarters

108 PATRIOT DRIVE, SUITE A
MIDDLETOWN, DE 19709, UNITED STATES

Sector

Medical

Auditor

KPMG LLP

Share holders

80

Employees

286

Zymeworks Inc. Statistics

Valuation Measures

Market Capitalization2

1.94B

Enterprise Value

1.88B

Enterprise Value/EBITDA(ttm)

-32.51

Price to Earnings Ratio(ttm)

--

Price to Sales(ttm)

14.18

Price to Book(mrq)

5.98

Price to Cash(ytd)

--

Profitability

Gross Margin(ttm)

-12.70%

Operating Margin(ttm)

-47.16%

Profit Margin(ttm)

-56.37%

Return on Equity(ttm)

-19.25%

Return on Invested Capital(ttm)

-19.34%

Return on Assets(ttm)

-14.97%

Income Statement

Revenue(ttm)

134.48M

Revenue Per Share(ttm)

1.80

Gross Profit(ttm)

-8.35M

EBITDA(ttm)3

-57.82M

Net Income Available to Common(ttm)

-63.43M

Diluted EPS(ttm)

-0.84

Share Statistics

Beta (5Y Monthly)

1.26

52-Week Change

91.40%

S&P 500 52-Week Change

14.46%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding1

74.84M

Dividend Yield

0.00%

Float4

49.76M

% Held by Insiders

33.51%

% Held by Institutions

92.89%

Balance Sheet

Total Cash(mrq)

251.93M

Total Cash Per Share(mrq)

3.37

Total Debt(mrq)

0.00

Total Debt/Equity(mrq)

0.00%

Current Ratio(mrq)

6.94%

Quick Ratio(mrq)

6.94%

Book Value Per Share(mrq)

4.26

Cash Flow

Operating Cash Flow Per Share(ytd)

-0.30

Free Cash Flow(ytd)

-23.69M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement